MX2020014163A - Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. - Google Patents

Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.

Info

Publication number
MX2020014163A
MX2020014163A MX2020014163A MX2020014163A MX2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A
Authority
MX
Mexico
Prior art keywords
solid forms
ynoyl
pyrazin
imidazo
pyrrolidin
Prior art date
Application number
MX2020014163A
Other languages
English (en)
Inventor
Fritz Blatter
Jerry Evarts
Tjeerd Barf
Tim Ingallinera
Edwin Aret
Cecile Krejsa
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020014163(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MX2020014163A publication Critical patent/MX2020014163A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

En algunas modalidades, la invención se refiere a formas sólidas cristalinas, incluyendo polimorfos, hidratos y formas de sal, de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pi razin-1-il)-N-(piridin-2-il)benzamida. En algunas modalidades, la invención también se refiere a composiciones farmacéuticas que contienen las formas sólidas cristalinas, y a métodos para tratar afecciones o trastornos administrando a un sujeto una composición farmacéutica que incluye las formas, incluyendo composiciones farmacéuticas y métodos para superar los efectos de los agentes reductores de ácido. Fórmula (I). (ver Fórmula).
MX2020014163A 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. MX2020014163A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188468P 2015-07-02 2015-07-02
US201562271708P 2015-12-28 2015-12-28
PCT/IB2016/053988 WO2017002095A1 (en) 2015-07-02 2016-07-01 Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Publications (1)

Publication Number Publication Date
MX2020014163A true MX2020014163A (es) 2022-09-29

Family

ID=56363881

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000179A MX2018000179A (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
MX2020014163A MX2020014163A (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000179A MX2018000179A (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.

Country Status (29)

Country Link
US (6) US9796721B2 (es)
EP (4) EP3954690B1 (es)
JP (3) JP6829215B2 (es)
KR (1) KR20180048593A (es)
CN (2) CN108349978B (es)
AU (3) AU2016286548B2 (es)
CA (1) CA2991096A1 (es)
CL (1) CL2017003445A1 (es)
CY (3) CY1124519T1 (es)
DK (3) DK3613745T3 (es)
ES (3) ES2946489T3 (es)
FI (1) FI3954690T3 (es)
HK (1) HK1250511A1 (es)
HR (3) HRP20211511T1 (es)
HU (3) HUE062258T2 (es)
IL (3) IL274066B (es)
LT (3) LT3317281T (es)
MA (1) MA50817B1 (es)
MD (1) MD3317281T2 (es)
MX (2) MX2018000179A (es)
MY (1) MY193514A (es)
PL (3) PL3613745T3 (es)
PT (3) PT3613745T (es)
RS (3) RS64195B1 (es)
RU (1) RU2018103913A (es)
SG (1) SG10201913796UA (es)
SI (3) SI3613745T1 (es)
WO (1) WO2017002095A1 (es)
ZA (2) ZA201800329B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3179991B1 (en) * 2014-08-11 2021-10-06 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
LT3317281T (lt) 2015-07-02 2020-07-27 Acerta Pharma B.V. (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamido kompozicijų kietosios formos
WO2018064797A1 (zh) 2016-10-05 2018-04-12 杭州领业医药科技有限公司 Acp-196的晶型及其制备方法和药物组合物
WO2018115965A1 (en) * 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
CA3058375A1 (en) 2017-03-27 2018-10-04 Tesaro, Inc. Niraparib compositions
TW201842908A (zh) * 2017-03-27 2018-12-16 美商提薩羅有限公司 尼拉帕尼(niraparib)調配物
US10717740B2 (en) 2017-06-13 2020-07-21 Dr. Reddy's Laboratories Limited. Solid forms of acalabrutinib and process for preparation thereof
WO2019041026A1 (en) * 2017-08-29 2019-03-07 Apotex Inc. NEW CRYSTALLINE FORMS OF ACALABRUTINIB
EA202090573A1 (ru) 2017-09-26 2020-09-07 Тесаро, Инк. Составы нирапариба
WO2019105359A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Acalabrutinib的晶型及其制备方法和用途
CA3087474A1 (en) 2018-01-05 2019-07-11 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of acalabrutinib, processes for preparation and use thereof
WO2019159097A1 (en) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Crystalline polymorphic forms of acalabrutinib
CN110650960B (zh) * 2018-04-26 2021-08-24 苏州科睿思制药有限公司 Acalabrutinib的新晶型及其制备方法和用途
EP3587421A1 (en) 2018-06-29 2020-01-01 Sandoz AG Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
WO2020053795A2 (en) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Process for the preparation of acalabrutinib and its intermediates
WO2020065667A1 (en) 2018-09-25 2020-04-02 Cipla Limited Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
US20220153744A1 (en) 2019-03-27 2022-05-19 Assia Chemical Industries Ltd. Solid state forms of acalabrutinib
WO2020225831A1 (en) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021135346A1 (zh) * 2019-12-31 2021-07-08 苏州科睿思制药有限公司 Acalabrutinib的新晶型及其制备方法和用途
WO2021239893A1 (en) 2020-05-29 2021-12-02 Bend Research, Inc. Amorphous solid dispersion of acalabrutinib
PE20230992A1 (es) 2020-06-19 2023-06-23 Acerta Pharma Bv Formas farmaceuticas de maleato de acalabrutinib
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
WO2022153330A1 (en) * 2021-01-13 2022-07-21 Natco Pharma Limited Pharmaceutical compositions comprising acalabrutinib
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
WO2023205279A1 (en) * 2022-04-19 2023-10-26 The Johns Hopkins University Improved raman spectroscopy with the addition of aromatic compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
CN1390220A (zh) 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
CA2542481A1 (en) 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazopyrazine tyrosine kinase inhibitors
US7534797B2 (en) 2004-04-02 2009-05-19 Osi Pharmaceuticals, Inc. 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
US8795723B2 (en) 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
WO2007061737A2 (en) 2005-11-17 2007-05-31 Osi Pharmaceuticals, Inc. FUSED BICYCLIC mTOR INHIBITORS
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US7651687B2 (en) 2006-03-13 2010-01-26 Osi Pharmaceuticals, Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
ATE531263T1 (de) 2006-09-22 2011-11-15 Pharmacyclics Inc Hemmer der bruton-tyrosinkinase
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
BRPI0821660A2 (pt) 2007-12-13 2015-06-16 Novartis Ag Combinações de agentes terapêuticos para tratamento de câncer
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
BR112012019765B1 (pt) 2010-02-08 2021-08-31 Merck Sharp & Dohme B.V Composto, e, uso de um composto
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
KR101537148B1 (ko) 2010-05-31 2015-07-15 오노 야꾸힝 고교 가부시키가이샤 푸리논 유도체
CA2800913C (en) 2010-06-03 2019-07-23 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
KR102052670B1 (ko) 2011-05-17 2019-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키나아제 저해제
EP2726077A4 (en) 2011-06-28 2014-12-10 Pharmacyclics Inc METHODS AND COMPOSITIONS FOR INHIBITING BONE RESORPTION
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2734523A1 (en) 2011-07-19 2014-05-28 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
CA2841886C (en) 2011-07-19 2016-08-16 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
KR102258778B1 (ko) 2011-10-19 2021-06-02 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
TW201441234A (zh) 2013-01-23 2014-11-01 Merck Sharp & Dohme Ｂｔｋ抑制劑
EA201591718A1 (ru) 2013-03-14 2016-05-31 Фармасайкликс Элэлси Комбинации ингибиторов тирозинкиназы брутона и ингибиторов cyp3a4
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
JP6368353B2 (ja) 2013-04-08 2018-08-01 バイエル ファーマ アクチエンゲゼルシャフト 置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類のリンパ腫治療への使用
JP6575952B2 (ja) 2013-04-08 2019-09-18 ファーマサイクリックス エルエルシー イブルチニブ併用療法
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
CN105979948A (zh) 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
KR101768402B1 (ko) 2013-12-13 2017-08-14 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
FR3021783B1 (fr) 2014-06-02 2016-05-13 Morpho Procede de validation de l'authenticite d'un element du corps humain
LT3317281T (lt) 2015-07-02 2020-07-27 Acerta Pharma B.V. (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamido kompozicijų kietosios formos

Also Published As

Publication number Publication date
EP3954690A1 (en) 2022-02-16
CN108349978B (zh) 2021-07-23
US20220177476A1 (en) 2022-06-09
US9796721B2 (en) 2017-10-24
CA2991096A1 (en) 2017-01-05
CN113480542A (zh) 2021-10-08
CY1124815T1 (el) 2022-11-25
LT3317281T (lt) 2020-07-27
HUE049989T2 (hu) 2020-11-30
PT3613745T (pt) 2021-10-14
PL3954690T3 (pl) 2023-08-14
RU2018103913A3 (es) 2019-12-31
WO2017002095A1 (en) 2017-01-05
CN108349978A (zh) 2018-07-31
HRP20230417T1 (hr) 2023-07-07
JP2021073235A (ja) 2021-05-13
SI3317281T1 (sl) 2020-08-31
ES2797987T3 (es) 2020-12-04
AU2016286548A1 (en) 2018-02-01
MD3317281T2 (ro) 2020-07-31
DK3954690T3 (da) 2023-06-06
RS64195B1 (sr) 2023-06-30
US20170029428A1 (en) 2017-02-02
MA50817B1 (fr) 2021-10-29
US11820777B2 (en) 2023-11-21
LT3613745T (lt) 2021-10-11
MX2018000179A (es) 2018-06-27
AU2020277123B2 (en) 2022-09-29
EP3954690B1 (en) 2023-04-05
JP6829215B2 (ja) 2021-02-10
EP3317281A1 (en) 2018-05-09
IL274066B (en) 2022-07-01
AU2020277123A1 (en) 2020-12-24
PT3317281T (pt) 2020-06-18
US20190337949A1 (en) 2019-11-07
LT3954690T (lt) 2023-05-25
IL256633A (en) 2018-02-28
JP2022120156A (ja) 2022-08-17
PL3317281T3 (pl) 2020-11-02
RS62455B1 (sr) 2021-11-30
SI3613745T1 (sl) 2021-12-31
EP3613745B1 (en) 2021-09-01
HUE056008T2 (hu) 2022-01-28
ES2946489T3 (es) 2023-07-19
CY1126103T1 (el) 2023-11-15
DK3317281T3 (da) 2020-06-15
DK3613745T3 (da) 2021-10-18
EP3317281B1 (en) 2020-04-22
CY1124519T1 (el) 2022-03-24
HRP20211511T1 (hr) 2021-12-24
ZA202000300B (en) 2022-03-30
SI3954690T1 (sl) 2023-07-31
MY193514A (en) 2022-10-17
HUE062258T2 (hu) 2023-10-28
US10167291B2 (en) 2019-01-01
US20180208596A1 (en) 2018-07-26
SG10201913796UA (en) 2020-03-30
IL256633B (en) 2020-05-31
ZA201800329B (en) 2022-04-28
KR20180048593A (ko) 2018-05-10
EP3613745A1 (en) 2020-02-26
RS60411B1 (sr) 2020-07-31
JP7091494B2 (ja) 2022-06-27
CL2017003445A1 (es) 2018-05-11
PT3954690T (pt) 2023-06-06
AU2016286548B2 (en) 2020-12-10
US10640509B2 (en) 2020-05-05
US20200255437A1 (en) 2020-08-13
AU2022291635A1 (en) 2023-02-02
RU2018103913A (ru) 2019-08-02
HRP20200934T1 (hr) 2020-09-18
US20220348582A1 (en) 2022-11-03
ES2895802T3 (es) 2022-02-22
EP4209493A1 (en) 2023-07-12
MA50817A (fr) 2021-04-21
FI3954690T3 (fi) 2023-05-31
HK1250511A1 (zh) 2018-12-21
IL274066A (en) 2020-06-30
US11059829B2 (en) 2021-07-13
IL293821A (en) 2022-08-01
PL3613745T3 (pl) 2022-01-31
JP2018522877A (ja) 2018-08-16

Similar Documents

Publication Publication Date Title
MX2020014163A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
NZ708593A (en) Novel pyrazole derivative
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12015501661A1 (en) Pyridone amides as modulators of sodium channels
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX359882B (es) Amidas como moduladores de canales de sodio.
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
GB201104267D0 (en) Pyrrolopyridineamino derivatives
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2009009154A (es) Derivados de espiro-pirano-pirazol.
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.